Rapport Therapeutics (NASDAQ:RAPP) Director Wendy Young Purchases 3,789 Shares of Company Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director Wendy Young acquired 3,789 shares of the company’s stock in a transaction that occurred on Thursday, October 22nd. The shares were bought at an average price of $26.39 per share, for a total transaction of $99,991.71. Following the completion of the acquisition, the director owned 13,289 shares of the company’s stock, valued at $350,696.71. This trade represents a 39.88% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Rapport Therapeutics Stock Up 5.9%

RAPP opened at $26.53 on Friday. Rapport Therapeutics, Inc. has a 12 month low of $23.75 and a 12 month high of $52.93. The firm’s fifty day simple moving average is $39.44 and its 200 day simple moving average is $39.02.

Rapport Therapeutics (NASDAQ:RAPP) last released its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, research analysts predict that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RAPP has been the subject of a number of research reports. William Blair assumed coverage on Rapport Therapeutics in a report on Tuesday, July 28th. They set an “outperform” rating for the company. Citigroup restated an “outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $66.00 price target on shares of Rapport Therapeutics in a research report on Tuesday. Wells Fargo & Company decreased their price target on shares of Rapport Therapeutics from $51.00 to $50.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $68.36.

Institutional Investors Weigh In On Rapport Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sterling Capital Management LLC boosted its stake in shares of Rapport Therapeutics by 597.9% during the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock worth $33,000 after buying an additional 843 shares during the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Rapport Therapeutics in the second quarter valued at about $888,000. Wellington Management Group LLP raised its holdings in Rapport Therapeutics by 11.2% during the second quarter. Wellington Management Group LLP now owns 86,988 shares of the company’s stock worth $3,625,000 after acquiring an additional 8,757 shares in the last quarter. Artia Global Partners LP bought a new stake in Rapport Therapeutics during the second quarter worth about $5,772,000. Finally, Bank of America Corp DE bought a new position in Rapport Therapeutics in the second quarter valued at approximately $3,170,000.

More Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 achieved both Phase 2 endpoints in bipolar mania. The candidate produced statistically significant placebo-adjusted improvements in YMRS and CGI-BP mania-severity scores. Rapport plans to begin Phase 3 trials, potentially expanding RAP-219’s commercial opportunity beyond epilepsy. Rapport Therapeutics Announces Positive Topline Results
• Positive Sentiment: Analysts increased or maintained bullish valuations. JonesTrading raised its target to $82, while BTIG reportedly lifted its target to $89. Raymond James raised its target to $86, and HC Wainwright reaffirmed its Buy rating. The consensus target is approximately $68.36, well above recent trading levels. BTIG price target increase
• Positive Sentiment: Company insiders made substantial open-market purchases. CFO Troy Ignelzi bought 5,500 shares, while four directors purchased an additional 52,594 shares. The combined purchases were worth approximately $1.57 million and may signal management confidence following the clinical update. SEC insider filings
• Neutral Sentiment: RAP-219’s move toward Phase 3 is an important milestone, but investors still face clinical, regulatory, financing, and commercialization uncertainty typical of a clinical-stage biotechnology company.
• Negative Sentiment: The clinical results may have been less decisive than some investors expected. Reports indicated that portions of the data narrowly met expectations, potentially limiting enthusiasm after the initial rally. Rapport also remains unprofitable; its latest quarterly loss exceeded analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. Rapport bipolar data report

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.